Geron Corp.

Geron Corp.

Geron Corp.

Overview
Date Founded

1990

Headquarters

149 COMMONWEALTH DRIVE, SUITE 2070, MENLO PARK, CA, 94025

Type of Company

Public

Employees (Worldwide)

17

Industries

Biotechnology
IT Consulting & Services
Medical Support Services

Company Description

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Contact Data
Trying to get in touch with decision makers at Geron Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman of the Board, President & Chief Executive Officer

Interim Executive Chairman

Chief Financial Officer

Executive Vice President & Chief Operating Officer

Chief Business Officer & Executive Vice President

Executive Vice President, Chief Legal Officer & Corporate Secretary

Executive Vice President & Chief Medical Officer

Executive Vice President, Corporate Strategy & Chief Commercial Officer

Vice President, Pharmacovigilance & Drug Safety

Executive Director & Medical Affairs

Board of Directors

Chairman of the Board, President & Chief Executive Officer at Geron Corp.

Former Interim Executive Chairman at Geron Corp.

Former Chief Operating Officer, Trustee & Executive Vice President at Sanford Burnham Prebys Medical Discovery Institute

President at Spiegel Consulting LLC

Founder, President & Chief Executive Officer at Calithera Biosciences, Inc.

Director at Reform Biologics LLC

Former Chief Procurement Officer & Head-Global Services at Eli Lilly & Company

Vice President & Chief Commercial Officer at Reata Pharmaceuticals, Inc.

Paths to Geron Corp.
Potential Connections via
Relationship Science
You
Geron Corp.
Recent Transactions
Details Hidden

Geron Corp. issued Common Stock

Details Hidden

Geron Corp. issued Common Stock

Details Hidden

Geron Corp. issued Common Stock

Transaction Advisors
Underwriter

Advised onGeron Corp. issued Common Stock

Underwriter

Advised onGeron Corp. issued Common Stock

Underwriter

Advised onGeron Corp. issued Common Stock

Legal Advisor

Advised onGeron Corp. issued Common Stock

Managing Director

Advised onGeron Corp. issued Common Stock

Legal Advisor

Advised onGeron Corp. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Cooley LLP

Legal Advisor

Partner at Latham & Watkins LLP

Advisor

Founder at Sosei Group Corp.

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Oncolys BioPharma, Inc. engages in the research and development of oncolytic viruses, drugs for serious infectious diseases, molecular targeted anti-cancer drugs, and tumor diagnostic agents. It also offers consulting services with regard to the research and development of biotechnology drugs. It operates through the following segments: Pharmaceutical and Diagnostics. The Pharmaceutical segments deals with the research, development, manufacture and sale of pharmaceutical products. The Diagnostics segment consists of the research, development, manufacture and sale of test drug and equipment, as well as the provision of inspection services. The company was founded by Yasuo Urata on March 18, 2004 and is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$261M
Total Enterprise Value
$12.9M
Earnings Per Share
$-0.15
Revenue
$1.07M
Total Equity
$178M
Net Profit
$-27M
EBITDAMargin
-2,909.38%
Enterprise Value Sales
12.15x
TEVNet Income
-0.48x
Debt TEV
0x
EBITDA
$-31M
Total Debt
$0
Three Year Compounded Annual Growth Rate Of Revenue
-69.17%
Five Year Compounded Annual Growth Rate Of Revenue
-3.64%
Suppliers
The University of Colorado Schools & Student Services | Boulder, CO

The University of Colorado advances the economy, health and culture of Colorado and beyond, educating more than 435,000 students who have become catalysts in business, arts, health and community growth. CU’s four campuses feature top-tier faculty and hands-on learning opportunities in an environment where students thrive.

The University of Texas - Southwestern Medical Center Schools & Student Services | Dallas, TX

UT Southwestern Medical Center is distinctive for its overall quality and for the strength of its three core missions of education, research, and patient care. These mission components are highly interdependent; each is integral to and enhances the others.UT Southwestern consists today of three degree-granting schools and a University Health System of hospitals and clinics. Its faculty is renowned for including six Nobel Laureates (one now Emeritus) and many members of the National Academy of Sciences and Institute of Medicine, and UT Southwestern Medical Center is either nationally ranked or rated as high performing in nearly a dozen specialties by U.S. News & World Report.

University of California Investment Services & Portfolio Management

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Geron Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Geron Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Geron Corp..